There are currently four monoclonal antibodies available that are directed against TNF: infliximab, adalimumab, golimumab and certolizumab. All of these agents are efficacious in RA, with clinical ...

He noted that in the longer term, J&J 's sales of Simponi Aria (golimumab) continue to grow in rheumatoid arthritis. The company has noted that s J&J has also filed sirukumab in the US and EU ...

in 2012 and J&J’s Simponi (golimumab) in 2013. In Europe, these therapies were introduced between 2006 and 2013. The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors ...

Objectives Infliximab, an anti-TNF agent, is used to treat sarcoidosis that does not respond to corticosteroids or second-line agents. The efficacy of other anti-TNF agents, non-TNF biologics and ...

Explore why INmune Bio, Inc. is a speculative Strong Buy for high-risk investors. Click for the upcoming catalysts that make ...

Original Medicare (parts A and B) covers most medically necessary rheumatoid arthritis (RA) treatments, including biologics. Medicare Part D covers Medicare-approved costs if RA biologics are self ...

Expert Rev Pharmacoeconomics Outcomes Res. 2012;12(3):319-333. The most recent biologic therapy to receive marketing approval, tocilizumab, was evaluated in a 24-week, randomized, placebo ...

Original Medicare covers most medically necessary treatments for rheumatoid arthritis (RA), including biologics like adalimumab (Humira), etanercept (Enbrel), infliximab (Remicade, Inflectra), and ...

MINNEAPOLIS — Fewer than half of women treated for high-grade cervical dysplasia subsequently received guidance-concordant surveillance, of whom one-third had an abnormal co-test result ...